615 related articles for article (PubMed ID: 25995732)
21. Dyslipidaemia in polycystic ovarian syndrome: different groups, different aetiologies?
Meirow D; Raz I; Yossepowitch O; Brzezinski A; Rosler A; Schenker JG; Berry EM
Hum Reprod; 1996 Sep; 11(9):1848-53. PubMed ID: 8921052
[TBL] [Abstract][Full Text] [Related]
22. Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome.
Kurek Eken M; Sahin Ersoy G; Yayla Abide C; Sanverdi İ; Devranoglu B; Kutlu T; Çevik Ö
J Obstet Gynaecol; 2019 Oct; 39(7):975-980. PubMed ID: 31064233
[TBL] [Abstract][Full Text] [Related]
23. The impact of lipid accumulation product (LAP) and visceral adiposity index (VAI) on clinical, hormonal and metabolic parameters in lean women with polycystic ovary syndrome.
Anik Ilhan G; Yildizhan B; Pekin T
Gynecol Endocrinol; 2019 Mar; 35(3):233-236. PubMed ID: 30303693
[TBL] [Abstract][Full Text] [Related]
24. The correlation of plasma omentin-1 with insulin resistance in non-obese polycystic ovary syndrome.
Yang HY; Ma Y; Lu XH; Liang XH; Suo YJ; Huang ZX; Lu DC; Qin YF; Luo ZJ
Ann Endocrinol (Paris); 2015 Oct; 76(5):620-7. PubMed ID: 26514948
[TBL] [Abstract][Full Text] [Related]
25. Retinol-binding protein in nonobese women with polycystic ovary syndrome.
Lee JW; Im JA; Lee DC; Lee HR; Shim JY
Clin Endocrinol (Oxf); 2008 May; 68(5):786-90. PubMed ID: 17986278
[TBL] [Abstract][Full Text] [Related]
26. Spectrum of metabolic dysfunction in relationship with hyperandrogenemia in obese adolescent girls with polycystic ovary syndrome.
Alemzadeh R; Kichler J; Calhoun M
Eur J Endocrinol; 2010 Jun; 162(6):1093-9. PubMed ID: 20371657
[TBL] [Abstract][Full Text] [Related]
27. L:A ratio, Insulin resistance and metabolic risk in women with polycystic ovarian syndrome.
Gupta V; Mishra S; Mishra S; Gupta V
Diabetes Metab Syndr; 2017 Dec; 11 Suppl 2():S697-S701. PubMed ID: 28529126
[TBL] [Abstract][Full Text] [Related]
28. Circulating FGF21 levels are related to nutritional status and metabolic but not hormonal disturbances in polycystic ovary syndrome.
Olszanecka-Glinianowicz M; Madej P; Wdowczyk M; Owczarek A; Chudek J
Eur J Endocrinol; 2015 Feb; 172(2):173-9. PubMed ID: 25411238
[TBL] [Abstract][Full Text] [Related]
29. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome.
Guzelmeric K; Alkan N; Pirimoglu M; Unal O; Turan C
Gynecol Endocrinol; 2007 Sep; 23(9):505-10. PubMed ID: 17852421
[TBL] [Abstract][Full Text] [Related]
30. Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesity.
Słopień R; Lewandowski K; Kolacz E; Zawilska K; Warenik-Szymankiewicz A
Gynecol Endocrinol; 2006 Nov; 22(11):651-4. PubMed ID: 17145652
[TBL] [Abstract][Full Text] [Related]
31. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M
Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091
[TBL] [Abstract][Full Text] [Related]
32. Serum adiponectin is independently associated with the metabolic syndrome in Hong Kong, Chinese women with polycystic ovary syndrome.
Ko JK; Li HW; Lam KS; Tam S; Lee VC; Yeung TW; Ho PC; Ng EH
Gynecol Endocrinol; 2016; 32(5):390-4. PubMed ID: 26699091
[TBL] [Abstract][Full Text] [Related]
33. Intrinsic factors rather than vitamin D deficiency are related to insulin resistance in lean women with polycystic ovary syndrome.
Sahin S; Eroglu M; Selcuk S; Turkgeldi L; Kozali S; Davutoglu S; Muhcu M
Eur Rev Med Pharmacol Sci; 2014 Oct; 18(19):2851-6. PubMed ID: 25339479
[TBL] [Abstract][Full Text] [Related]
34. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
35. Emergence of ovulatory cycles with aging in women with polycystic ovary syndrome (PCOS) alters the trajectory of cardiovascular and metabolic risk factors.
Carmina E; Campagna AM; Lobo RA
Hum Reprod; 2013 Aug; 28(8):2245-52. PubMed ID: 23595974
[TBL] [Abstract][Full Text] [Related]
36. Adverse Effects of Selected Markers on the Metabolic and Endocrine Profiles of Obese Women With and Without PCOS.
Daghestani MH; Daghestani MH; Warsy A; El-Ansary A; Omair MA; Omair MA; Hassen LM; Alhumaidhi EM; Al Qahtani B; Harrath AH
Front Endocrinol (Lausanne); 2021; 12():665446. PubMed ID: 34122339
[TBL] [Abstract][Full Text] [Related]
37. Relationship between body composition, insulin resistance, and hormonal profiles in women with polycystic ovary syndrome.
Zhang H; Wang W; Zhao J; Jiao P; Zeng L; Zhang H; Zhao Y; Shi L; Hu H; Luo L; Fukuzawa I; Li D; Li R; Qiao J
Front Endocrinol (Lausanne); 2022; 13():1085656. PubMed ID: 36699018
[TBL] [Abstract][Full Text] [Related]
38. Glucose intolerance in Japanese patients with polycystic ovary syndrome.
Kurioka H; Takahashi K; Miyazaki K
Arch Gynecol Obstet; 2007 Mar; 275(3):169-73. PubMed ID: 16972071
[TBL] [Abstract][Full Text] [Related]
39. Vitamin D in polycystic ovary syndrome: Relationship to obesity and insulin resistance.
Joham AE; Teede HJ; Cassar S; Stepto NK; Strauss BJ; Harrison CL; Boyle J; de Courten B
Mol Nutr Food Res; 2016 Jan; 60(1):110-8. PubMed ID: 26255991
[TBL] [Abstract][Full Text] [Related]
40. Value of the triglyceride-glucose index and non-traditional blood lipid parameters in predicting metabolic syndrome in women with polycystic ovary syndrome.
Zhang L; Wang H; Ma Q; Liu Y; Chen A; Lu J; Ren L
Hormones (Athens); 2023 Jun; 22(2):263-271. PubMed ID: 36790635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
